Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement
With the contribution of the European Association of Preventive Cardiology (EAPC), the Association for Acute CardioVascular Care (ACVC), and the Heart Failure Association (HFA) of the ESC
Mucosal COVID-19 vaccines in clinical development
Mucosal vaccines are designed to elicit both a strong systemic and mucosal immune response gaining importance as the next generation of vaccines
Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG and BA.3.2 following KP.2 monovalent mRNA vaccination
The evolution of SARS-CoV-2 has resulted in antigenically distinct variants that challenge vaccine-induced immunity.
Respiratory viral infections awaken metastatic breast cancer cells in lungs
Understanding the mechanisms that disrupt the quiescence of dormant disseminated cancer cells (DCCs) is crucial for addressing metastatic progression.
News
Policy & Recommendations
The European Commission invests in the development of innovative products against respiratory viruses
The technology provides a universal solution to respiratory viruses, regardless of an individual's immune history – for example, people who do not sufficiently respond to a vaccine, or don't get vaccinated
News
Policy & Recommendations
EU Working Group on Respiratory Care kick-off meeting
This group will lead the development of a Call to Action to advocate for better access to treatments, in particular COVID- 19.
Cardiac Events in Adults Hospitalized for Respiratory Syncytial Virus vs COVID-19 or Influenza
What is the risk of acute cardiovascular complications in adults hospitalized for respiratory syncytial virus (RSV) vs influenza or SARS-CoV-2 Omicron infection?
FluCov-Bulletin – May 2025
FluCov project: combining data from around the world to better understand the co-circulation of influenza and COVID-19
